News

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process.

Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and other commodities in highly energetically favorable (high yield, high purity) production. Allozymes is optimizing key enzymes in the pathway to meet large-scale production specifications. The collaboration includes Allozymes’ cutting edge microfluidics-based protein engineering platform to achieve what was previously thought impossible: analyzing up to 20 million enzyme variants a day, delivering superior success rates, and dramatically reducing development timelines for novel enzymes.

“Optimizing enzymes for industrial-scale production requires precision, speed, and innovation, and our collaboration with Bonumose exemplifies this,” said Akbar Vahidi, Chief Technology Officer of Allozymes. “By leveraging our microfluidics-based protein engineering platform, we have been able to rapidly enhance key enzymes, significantly improving the process efficiency and scalability. The early results are promising, and we are confident that this partnership will unlock new possibilities in sustainable and cost-effective ingredient production.”

Dr. Daniel Wichelecki, Bonumose’s Chief Scientific Officer and Co-Founder, states, “Our mission is to produce healthy food and supplement ingredients in a low-cost, scalable production process. Our development collaborator Allozymes has shown promising results in the initial phases of our collaboration. We are on track and confident to meet our developmental objectives.”

The companies are pleased with the important milestone in both companies’ agenda of leveraging the use of enzymes to accelerate timelines and meet ambitious targets for producing beneficial ingredients to meet global needs for healthy food, dietary supplements, and other important categories.

“Our goal is to drive the future of sustainable food ingredient production through enzyme innovation,” said Akbar Vahidi. “Our collaboration with Bonumose is a critical part of this mission and we aim to demonstrate a successful model on how Allozymes enables innovation in the food ingredient market. With our unique platform, we are confident that we’ll continue to reduce development timelines and enhance performance, setting a new benchmark in the industry.”

 

Read more here.

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns